Is This Drugmaker Making the Right Moves, in the Right Places?

AstraZeneca announced that it will move its headquarters to Cambridge, England. Is this the right move?

Max Macaluso
Max Macaluso
Mar 18, 2013 at 6:30PM
Health Care

AstraZeneca (NYSE:AZN) is commonly recognized as one of the most fragile Big Pharma stocks on the market. While its peers, such as GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), have restructured their R&D strategies or spun out divisions, AstraZeneca has only recently started to make changes. Last autumn, the company suspended its share-buyback program in an effort to preserve cash, reshuffled its management team, and today announced its boldest move yet: It's moving its headquarters and shifting focus to three primary R&D sites. In the following video, Motley Fool analyst Max Macaluso discusses why investors should take notice of the company's bold plans.